CES Unveiled Amsterdam Showcases Tech Changing Lives for Good
The Consumer Technology Association (CTA)TM today made several major announcements at CES Unveiled Amsterdam, a tech event bringing together top media, exhibitors and investors to celebrate European innovation and experience a sneak peek of the trends expected at CES® 2019. Owned and produced by CTA, CES 2019 will run from January 8-11, 2019, in Las Vegas, Nevada.
To commemorate World Tourism Day today, CTA announced a brand-new tourism area at CES 2019 to highlight the importance of technology and innovation in tourism. Attendees will be able to see and experience how technology helps customize and advance the travel experience. In addition to show floor exhibits, conference programming will dive into the role that tech plays in helping the global travel and tourism industry create personalized experiences that also provide sustainable economic growth opportunities for local communities.
Announced for the first time at CES Unveiled Amsterdam, CTA’s fourth book Ninja Future: Secrets to Success in the New World of Innovation (HarperCollins, 2019), will be released at CES 2019. In the book, author Gary Shapiro, president and CEO, CTA, explains the evolving technological landscape - breakthroughs underway now and those we can only envision. Drawing on the insights he has gleaned as a martial arts black belt, he covers how businesses and governments can move to succeed in today’s turbulent environment by adopting the mindset of “ninjas”—adapting to technological change to capitalize on opportunities at lightning speed. Shapiro is also the New York Times best-selling author of Ninja Innovation: The Ten Killer Strategies of the World’s Most Successful Businesses (HarperCollins, 2013) and The Comeback: How Innovation Will Restore the American Dream (Beaufort, 2011).
Additionally, 31 tech companies from the Netherlands and the surrounding region were announced as CES® 2019 Innovation Honorees. Among them, Dutch company EVBox was honored in the Smart Energy category and Qoobi was honored in the High Performance Home Audio/Video category.
“The companies recognized as this year’s CES Innovation honorees represent the drive that is taking our global industry to new heights,” said Karen Chupka, executive vice president, CES, CTA. “The products honored today offer solutions to some of the world’s most pressing challenges and will change our lives and our world for the better.”
The remaining Innovation honorees will be announced at CES Unveiled Paris on October 3, 2018, and CES Unveiled New York on November 8, 2018. The full list of Honorees will be posted online at CES.tech and showcased at CES 2019, January 8-11.
Executives also announced that CTA will again partner with StartupDelta for CES 2019. Representing the Netherland’s commitment to innovation, StartupDelta will bring a delegation of Dutch startups to CES 2019 to be featured in Eureka Park, the startup hub of CES.
Now in its second year, CES Unveiled Amsterdam brought together 634 attendees from 19 countries, including 64 exhibitors from the Netherlands and surrounding regions. Continuing the focus and celebration of European innovation, CES Unveiled Paris will take place next Wednesday, October 3.
CES 2019 will showcase life-changing technology across every major industry, featuring 4,500 companies across 2.75M net square feet (260K net square meters) of exhibit space. The show provides access to the very latest transformative tech such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, sports, machine intelligence and more. New areas at CES 2019 include the Tourism Marketplace, as well as the recently announced Resilience area, focused on technologies that keep the world healthy, safe, warm, fed and secure in the face of adversity.
High-definition video b-roll from CES is available for easy download on CESbroll.com . See exclusive photos from the CES show floor, keynotes, conference sessions, events and award ceremonies in the CES photo gallery .
CES® is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. Owned and produced by the Consumer Technology Association (CTA)TM, it attracts the world's business leaders and pioneering thinkers. Check out CES video highlights. Follow CES online at CES.tech and on social.
About Consumer Technology Association:
Consumer Technology Association (CTA)™ is the trade association representing the $377 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best-known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
Unveiled New York
November 8, New York, NY
Unveiled Las Vegas
January 6, Las Vegas, NV
CES 2019 - Register
January 8-11, Las Vegas, NV
June 11-13, Shanghai, China
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an